Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | DRD4 | P21917 | 4/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4820190 | 0.87 | KDM4E (0.48) | ALDH1A1KDM4EPBRM1SMN1; SMN2HRH3 | |
| SCHEMBL4814888 | 0.87 | TSHR (0.49) | ALDH1A1DRD4DRD2KDM4EHTT | |
| SCHEMBL4815663 | 0.79 | HRH3 (0.48) | ALDH1A1PBRM1FAAHHRH3 | |
| SCHEMBL4814820 | 0.78 | FAAH (0.46) | ALDH1A1KDM4EHTTPBRM1FAAH | |
| SCHEMBL4896210 | 0.76 | AKR1C3 (0.60) | ALDH1A1FAAHSMN1; SMN2HRH3TSHR | |
| SCHEMBL4815397 | 0.75 | LMNA (0.49) | ALDH1A1PBRM1LMNAHRH3 | |
| SCHEMBL4819242 | 0.75 | KDM4E (0.56) | ALDH1A1KDM4EUSP2SMN1; SMN2HRH3 | |
| SCHEMBL4814489 | 0.75 | HRH3 (0.56) | ALDH1A1KDM4EHTTPBRM1SMN1; SMN2 | |
| SCHEMBL4816573 | 0.74 | GPR119 (0.55) | SMN1; SMN2HRH3 | |
| SCHEMBL4894879 | 0.74 | ALDH1A1 (0.49) | ALDH1A1KDM4EPBRM1SMN1; SMN2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | ALDH1A1 3901/4885DRD4 4842/4885DRD2 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.